Multiple clinical trials are underway targeting both PVR (using NTX-1088 [15, 17] or the PVR partner TIGIT) and PD-L1/PD-1 (https://clinicaltrials.gov/ct2/show/NCT05378425?term=pvr&cond=Cancer&draw=2&rank=1, https://clinicaltrials.gov/ct2/results?cond=Cancer&term=tigit+pd-l1&cntry=&state=&city=&dist=&Search=Search), and our results suggest that such efforts may be particularly effective against RB1/TP53-deficient TNBC. This evidence concerns the gene CD274 and cancer.